Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey.

摘要: Abstract Background Intralesional triamcinolone acetonide (TAC) is a well-established treatment for keloids and hypertrophic scars. The present text provides systematic review of all previously reported cases Cushing's syndrome resulting from intralesional TAC in an effort to discover whether association exists between dosage or frequency injection the subsequent development syndrome. Data collected multinational survey plastic surgeons presented discussed understand current trends use TAC. Recommendations early recognition syndrome, dosages children, follow up guidelines are presented. Methods A literature 1950 2012 was performed evaluate outcomes following used confidential sent 4125 surgeons, 102 responses 9 countries were received. Results total 18 after have been English world literature. Survey data reveals that at least 30% (25/84) exceed recommended 47% (46/97) not aware as possible complication Conclusions has multiple times Published suggests administered within most recent recommendations does appear place adult patients increased risk developing Children be yet insufficient currently exist with regard their safe dosage. should 30 mg per month children while noting one case resulted smaller dose. Diligent patient education advised any treated so complications can recognized addressed promptly.